SCHEMBL2005342

SCHEMBL2005342

O=C1CN(Cc2ccc(-c3cccc(CNC4CCOCC4)c3)cc2)C(=O)N1CC(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 1/20 0.41
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
OPRM1 P35372 2/20 0.38
OPRK1 P41145 2/20 0.38
MAP4K4 O95819 1/20 0.38
ENPP2 Q13822 1/20 0.37
CARM1 Q86X55 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
PRKD1 Q15139 3/20 0.36
HDAC6 Q9UBN7 1/20 0.36
MAPK3 P27361 1/20 0.36
MAPK1 P28482 1/20 0.36
PARP1 P09874 3/20 0.35
MTOR P42345 1/20 0.35
GRM2 Q14416 1/20 0.35
MEN1 O00255 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
BCHE P06276 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2004612 0.87 PARP1 (0.43) OPRM1OPRK1ENPP2HDAC6MAPK3
SCHEMBL838707 0.83 TRPV3 (0.38) OPRM1OPRK1PRKD1MAPK3MAPK1
SCHEMBL2005526 0.82 PARP1 (0.39) ENPP2HDAC6MAPK3MAPK1PARP1
SCHEMBL2004457 0.82 PARP1 (0.39) ENPP2HDAC6MAPK3MAPK1PARP1
SCHEMBL2004454 0.82 PARP1 (0.39) ENPP2HDAC6MAPK3MAPK1PARP1
SCHEMBL840103 0.79 MAPK1 (0.40) OPRM1OPRK1MAP4K4HDAC6MAPK3
SCHEMBL1997682 0.75 PARP1 (0.44) OPRM1OPRK1ENPP2HDAC6MAPK3
SCHEMBL1998985 0.71 ENPP2 (0.48) PDCD1CD274OPRM1OPRK1ENPP2
SCHEMBL1995187 0.70 PARP1 (0.39) OPRM1OPRK1ENPP2HDAC6MAPK3
SCHEMBL1999457 0.70 PARP1 (0.39) OPRM1OPRK1ENPP2HDAC6MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP claimed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 HTR5A 283/4885PDCD1 829/4885CD274 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.